We investigated the effect of the
angiotensin-converting enzyme (
ACE) inhibitor captopril in a clinically relevant ovine model of
smoke and
burn injury, with special reference to oxidative stress and activation of
poly(ADP-ribose) polymerase, in the lung and in circulating leukocytes. Female, adult sheep (28-40 kg) were divided into three groups. After
tracheostomy and under deep
anesthesia, both vehicle-control-treated (n = 5) and
captopril-treated (20 mg/kg per day, i.v., starting 0.5 h before the injury) (n = 5) groups were subjected to 2 × 20%, third-degree
burn injury and were insufflated with 48 breaths of cotton
smoke. A
sham group not receiving
burn/
smoke was also studied (n = 5). Animals were mechanically ventilated and fluid resuscitated for 24 h in the awake state.
Burn and
smoke injury resulted in an upregulation of ACE in the lung, evidenced by immunohistochemical determination and Western blotting.
Burn and
smoke injury resulted in pulmonary dysfunction, as well as systemic hemodynamic alterations.
Captopril treatment of
burn and
smoke animals improved PaO2/FiO2 ratio and pulmonary shunt fraction and reduced the degree of lung
edema. There was a marked increase in PAR levels in circulating leukocytes after
burn/
smoke injury, which was significantly decreased by
captopril. The pulmonary level of ACE and the elevated pulmonary levels of
transforming growth factor β in response to
burn and
smoke injury were significantly decreased by
captopril treatment. Our results suggest that the
ACE inhibitor captopril exerts beneficial effects on the pulmonary function in
burn/
smoke injury. The effects of the
ACE inhibitor may be related to the prevention of
reactive oxygen species-induced
poly(ADP-ribose)polymerase overactivation.
Angiotensin-converting enzyme inhibition may also exert additional beneficial effects by inhibiting the expression of the profibrotic mediator
transforming growth factor β.